keyword
MENU ▼
Read by QxMD icon Read
search

Symptom management prostate cancer

keyword
https://www.readbyqxmd.com/read/28619632/enhancing-prostate-cancer-survivorship-care-through-self-management
#1
REVIEW
Ted A Skolarus, Daniela Wittmann, Sarah T Hawley
The lack of clear roles for prostate cancer survivorship care providers places prostate cancer survivors at significant risk of inappropriate use of services delivered piecemeal by different providers, persistent bothersome symptoms, and silent suffering. Optimizing quality of care for prostate cancer survivors hinges on decreasing fragmentation of care, and providing quality symptom management. This is achieved through comprehensive, appropriate medical, surgical, pharmacological and psychosocial care, coupled with self-management, as highlighted in several recent resources addressing long-term and late effects of treatment...
June 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28609648/when-no-treatment-is-the-best-treatment-active-surveillance-strategies-for-low-risk-prostate-cancers
#2
REVIEW
V Stavrinides, C C Parker, C M Moore
Although the incidence of prostate cancer is rising due to PSA screening and increased life expectancy, the metastatic potential of low-grade, organ-confined disease remains low. An increasing number of studies suggest that radical treatment in such cases confers little or no survival benefit at a significant cost to morbidity. Active surveillance is a promising management approach of such low-risk cancers: eligible patients are selected based on clinical and pathological findings at diagnosis and are regularly monitored with digital rectal examinations, PSA testing and biopsies...
May 23, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28573637/clinical-significance-of-androgen-secretion-disorders-in-men-with-a-malignancy
#3
REVIEW
Pawel J Wiechno, Grazyna M Poniatowska, Wojciech Michalski, Jakub Kucharz, Malgorzata Sadowska, Joanna Jonska-Gmyrek, Karol Nietupski, Joanna Rzymowska, Tomasz Demkow
Cancer and its treatment can lead in men to testosterone deficiency, accompanied by somatic and mental symptoms. Germ cell tumours and their treatment may disturb the pituitary-gonadal axis, hence leading to significant clinical abnormalities. In some prostate cancer patients, castration, temporary or permanent, is a desired therapeutic condition. Yet, it is burdened with various side effects of complex intensity and significance. Last but not least, patients in the terminal stage of a malignancy present with low testosterone concentrations as a part of anorexia-cachexia syndrome...
July 2017: Medical Oncology
https://www.readbyqxmd.com/read/28571827/effect-on-overall-survival-of-locoregional-treatment-in-a-cohort-of-de-novo-metastatic-prostate-cancer-patients-a-single-institution-retrospective-analysis-from-the-royal-marsden-hospital
#4
Diletta Bianchini, David Lorente, Pasquale Rescigno, Zafeiris Zafeiriou, Elena Psychopaida, Hazel O'Sullivan, Mervyn Alaras, Michael Kolinsky, Semini Sumanasuriya, Mariane Sousa Fontes, Joaquin Mateo, Raquel Perez Lopez, Nina Tunariu, Nikolaos Fotiadis, Pardeep Kumar, Alison Tree, Nicholas Van As, Vincent Khoo, Chris Parker, Rosalind Eeles, Alan Thompson, David Dearnaley, Johann S de Bono
BACKGROUND: The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on overall survival (OS) hypothesizing that this could improve outcome through better local disease control and the induction of an antitumor immune response (abscopal effect). PATIENTS AND METHODS: M1 at diagnosis PCa patients referred to the Prostate Targeted Therapy Group at the Royal Marsden between June 2003 and December 2013 were identified...
April 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28562375/exercise-medicine-for-advanced-prostate-cancer
#5
Nicolas H Hart, Daniel A Galvão, Robert U Newton
PURPOSE OF REVIEW: Exercise is a provocative medicine, known for its preventive, complimentary and rehabilitative role in the management of cancer. Impressively, exercise is also emerging as a synergistic and targeted medicine to enhance symptom control, modulate tumour biology and delay disease progression, with the potential to increase overall survival. Given the complex clinical presentation of advanced prostate cancer patients and their omnipresent comorbidities, this review describes the current and potential role of exercise medicine in advanced prostate cancer...
June 1, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28541420/surgical-decompression-of-high-grade-spinal-cord-compression-from-hormone-refractory-metastatic-prostate-cancer
#6
Muhammad Omar Chohan, Sweena Kahn, Gustav Cederquist, Anne S Reiner, Joseph Schwab, Ilya Laufer, Mark Bilsky
BACKGROUND: Spine and nonspine skeletal metastases occur in more than 80% of patients with prostate cancer. OBJECTIVE: To examine the characteristics of the patient population undergoing surgery for the treatment of prostate cancer metastatic to the spine. METHODS: A retrospective chart review was performed on all patients treated at our institution from June 1993 to August 2014 for surgical management of metastatic spine disease from prostate cancer...
May 24, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28529549/abiraterone-acetate-and-prednisone-in-chemotherapy-na%C3%A3-ve-prostate-cancer-patients-rationale-evidence-and-clinical-utility
#7
REVIEW
E David Crawford, Neal D Shore, Daniel P Petrylak, Celestia S Higano, Charles J Ryan
Abiraterone acetate 1000 mg/day, combined with prednisone 5 mg PO twice daily, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate is the oral prodrug of abiraterone, a specific CYP17 inhibitor that blocks androgen biosynthesis within the adrenal glands, testes and tumor microenvironment. In a phase III trial of men with asymptomatic or minimally symptomatic, chemotherapy-naïve mCRPC, treatment with oral abiraterone acetate plus prednisone led to a statistically significant improvement in the co-primary endpoints of overall survival and radiographic progression-free survival when compared with placebo plus prednisone...
May 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28479762/transurethral-resection-of-prostate-in-benign-prostatic-enlargement-with-underactive-bladder-a-retrospective-outcome-analysis
#8
Ashok Kumar Sokhal, Rahul Janak Sinha, Bimalesh Purkait, Vishwajeet Singh
PURPOSE: The purpose of this study was to evaluate the clinical outcome and efficacy of transurethral resection of the prostate in patients of benign prostatic enlargement (BPE) with underactive bladder. MATERIALS AND METHODS: Retrospective study of 174 patients, who underwent transurethral resection of prostate (TURP) between 2008 and 2015, for lower urinary tract symptoms with BPE with bladder underactivity. Clinical history, physical examination, renal function test, urinalysis, cystourethroscopy, transabdominal or transrectal ultrasonography, and urodynamic study were recorded...
April 2017: Urology Annals
https://www.readbyqxmd.com/read/28479477/practice-patterns-in-the-diagnosis-and-management-of-hypogonadism-a-survey-of-smsna-members
#9
Faysal A Yafi, Nora M Haney, James Anaissie, Kenneth J DeLay, Landon Trost, Mohit Khera, Wayne J G Hellstrom
OBJECTIVE: To describe practice patterns in the diagnosis and treatment of hypogonadism, as the optimal approaches are controversial. Multiple therapeutic options are currently available for hypogonadal men and treatment patterns vary considerably. The safety of testosterone therapy (TTh) remains understudied. METHODS: A 23-question survey regarding diagnosis and treatment of hypogonadism was sent to all members of the Sexual Medicine Society of North America (SMSNA)...
May 4, 2017: Urology
https://www.readbyqxmd.com/read/28462790/contemporary-spinal-oncology-treatment-paradigms-and-outcomes-for-metastatic-tumors-to-the-spine-a-systematic-review-of-breast-prostate-renal-and-lung-metastases
#10
REVIEW
Amy Yao, Christopher A Sarkiss, Travis R Ladner, Arthur L Jenkins
Metastatic spinal disease most frequently arises from carcinomas of the breast, lung, prostate, and kidney. Management of spinal metastases (SpM) is controversial in the literature. Recent studies advocate more aggressive surgical resection than older studies which called for radiation therapy alone, challenging previously held beliefs in conservative therapy. A literature search of the PubMed database was performed for spinal oncology outcome studies published in the English language between 2006 and 2016...
July 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28434181/management-options-for-biochemically-recurrent-prostate-cancer
#11
REVIEW
Farhad Fakhrejahani, Ravi A Madan, William L Dahut
Prostate cancer is the most common solid tumor malignancy in men worldwide. Treatment with surgery and radiation can be curative in organ-confined disease. Unfortunately, about one third of men develop biochemically recurrent disease based only on rising prostate-specific antigen (PSA) in the absence of visible disease on conventional imaging. For these patients with biochemical recurrent prostate cancer, there is no uniform guideline for subsequent management. Based on available data, it seems prudent that biochemical recurrent prostate cancer should initially be evaluated for salvage radiation or prostatectomy, with curative intent...
May 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28429147/docetaxel-related-fatigue-in-men-with-metastatic-prostate-cancer-a-descriptive-analysis
#12
A R T Bergin, E Hovey, A Lloyd, G Marx, P Parente, T Rapke, P de Souza
PURPOSE: Fatigue is a prevalent and debilitating side effect of docetaxel chemotherapy in metastatic prostate cancer. A better understanding of the kinetics and nature of docetaxel-related fatigue may provide a framework for intervention. METHODS: This secondary analysis was performed using the MOTIF database, from a phase III, randomised, double-blind, placebo-controlled study of modafinil (200 mg/day for 15 days) for docetaxel-related fatigue in men with metastatic prostate cancer [1]...
April 20, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28420419/optimizing-veteran-centered-prostate-cancer-survivorship-care-study-protocol-for-a-randomized-controlled-trial
#13
Ted A Skolarus, Tabitha Metreger, Soohyun Hwang, Hyungjin Myra Kim, Robert L Grubb, Jeffrey R Gingrich, Sarah T Hawley
BACKGROUND: Although prostate cancer is the most common cancer among veterans receiving care in the Veterans Health Administration (VA), more needs to be done to understand and improve survivorship care for this large population. This study, funded by VA Health Services Research & Development (HSR&D), seeks to address the need to improve patient-centered survivorship care for veterans with prostate cancer. METHODS/DESIGN: This is a two-armed randomized controlled trial (RCT) with a target enrollment of up to 325 prostate cancer survivors per study arm (total anticipated n = 600)...
April 18, 2017: Trials
https://www.readbyqxmd.com/read/28390646/first-line-management-of-metastatic-castrate-resistant-prostate-cancer-patients-audit-of-real-life-practices
#14
Anthony Turpin, David Pasquier, Christophe Massard, Jean-François Berdah, Stéphane Culine, Nicolas Penel
BACKGROUND: No reliable guidelines are available for choosing the best option between docetaxel and new hormonal therapies (NHTs) (i.e., abiraterone and enzalutamide) in first-line therapy for metastatic castration-resistant prostate cancer (mCRPC) patients. We performed an audit of real-life practices. METHODS: We built an online questionnaire and distributed it with the help of French oncology networks. This questionnaire was sent to 481 physicians who treat patients with mCRPC...
April 5, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28382641/differences-in-fatigue-severity-in-a-sample-of-adult-cancer-patients
#15
Cindy S Tofthagen, Xusheng Chen, Elsa Pedro, Leorey N Saligan, Velda J Gonzalez
OBJECTIVE: To describe differences in fatigue severity in a sample of adult Puerto Rican patients during and post cancer treatments. BACKGROUND: Hispanics, including Puerto Ricans, are an understudied population who are underrepresented in clinical trials, especially in symptom research. Although symptom management is a clinical priority in oncology care, treatment-related differences in Puerto Rican cancer patients' report of fatigue severity has not been well described...
April 5, 2017: Journal of Clinical Nursing
https://www.readbyqxmd.com/read/28379852/unmet-supportive-care-needs-of-men-with-locally-advanced-and-metastatic-prostate-cancer-on-hormonal-treatment-a-mixed-methods-study
#16
Catherine Paterson, Sławomir Grzegorz Kata, Ghulam Nandwani, Debi Das Chaudhury, Ghulam Nabi
BACKGROUND: Men affected by prostate cancer who are undergoing hormone therapy can endure a range of symptoms that can adversely affect quality of life. Little research has been conducted to date, to understand the specific unmet supportive care needs of this patient group within the context of current service delivery. OBJECTIVE: The aim of this study was to understand the experiences of unmet supportive care needs of men affected by prostate cancer on hormone therapy in the United Kingdom...
April 4, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28366592/patients-preferences-for-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-a-discrete-choice-experiment
#17
Lina Eliasson, Hayley M de Freitas, Lindsay Dearden, Brian Calimlim, Andrew J Lloyd
PURPOSE: Patient treatment preferences are increasingly being used to inform health care decision making. This discrete choice experiment assessed how men perceive the risks and benefits of hypothetical treatment options for metastatic castrate-resistant prostate cancer (mCRPC). METHODS: Treatment attributes for inclusion were identified through a review of the literature and product labels. Expert interviews confirmed clinical appropriateness and patient relevance of the attributes, which included effectiveness (delay in months before chemotherapy), steroid use, possible drug interactions (additional hospital visits for monitoring), fogginess (effects on cognition and memory), fatigue (extreme tiredness), food restrictions, and bone pain...
March 30, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28352980/symptom-clusters-for-revising-scale-membership-in-the-analysis-of-prostate-cancer-patient-reported-outcome-measures-a-secondary-data-analysis-of-the-medical-research-council-rt01-trial-iscrtn47772397
#18
Agnieszka Lemanska, Tao Chen, David P Dearnaley, Rajesh Jena, Matthew R Sydes, Sara Faithfull
PURPOSE: To investigate the role of symptom clusters in the analysis and utilisation of patient reported outcome measures (PROMs) for data modelling and clinical practice. To compare symptom clusters with scales, and to explore their value in PROMs interpretation and symptom management. METHODS: A dataset called RT01 (ISCRTN47772397) of 843 prostate cancer patients was used. PROMs were reported with the University of California, Los Angeles Prostate Cancer Index (UCLA-PCI)...
March 28, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28349190/-when-should-the-primary-tumor-of-metastatic-bladder-or-prostate-cancer-be-treated-using-a-nonsurgical-regimen
#19
D Bottke, C Bolenz, S Ott, A Cebulla, T Wiegel
BACKGROUND: Patients with metastatic and locally advanced bladder or prostate cancer may suffer from pelvic symptoms such as pain, obstruction, and hemorrhage. Local tumor growth is associated with significant morbidity and systemic therapy is often ineffective. Local therapies such as bladder irrigation, transurethral resection of the prostate, and fulguration of bleeding vessels provide relief but often require repeated treatments. OBJECTIVES: The aim of this work was to review the current status of palliative pelvic radiotherapy for metastatic bladder and prostate cancer...
March 27, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28318726/low-risk-prostate-cancer-identification-management-and-outcomes
#20
REVIEW
Marco Moschini, Peter R Carroll, Scott E Eggener, Jonathan I Epstein, Markus Graefen, Rodolfo Montironi, Christopher Parker
CONTEXT: The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing. OBJECTIVE: In this collaborative review article, we examine recent literature regarding low-risk PCa and the available prognostic and therapeutic options. EVIDENCE ACQUISITION: We performed a literature review of the Medline, Embase, and Web of Science databases. The search strategy included the terms: prostate cancer, low risk, active surveillance, focal therapy, radical prostatectomy, watchful waiting, biomarker, magnetic resonance imaging, alone or in combination...
March 15, 2017: European Urology
keyword
keyword
3371
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"